Aciont
® Inc. is a specialty biopharmaceutical company endeavoring to become the world
leader in commercializing localized, non-invasive, controlled and sustained release back of the eye therapeutics for
sight threatening diseases such as severe uveitis, diabetic macular edema and age-related macular degeneration.
Aciont’s goal is to provide ophthalmologists substantially greater freedom in treating and/or preventing chronic eye
diseases through optimal drug dosing and improved patient/physician compliance.
Our Visulex® drug delivery system uses an easy to administer scleral lens shaped eye
applicator worn for less than 10 minutes.
The timing is right for the next wave of Back of the Eye (BOTE) therapies as it will most likely require drug delivery differentiation, and Aciont is on the forefront of the wave.
Many of the leading BOTE drug delivery technologies are invasive in nature because they target the eye’s interior regions such as the vitreous or retina, which often cannot be reached via conventional methods (e.g., eye drops).
One revolutionary aspect of Aciont’s technology platform is the incorporation of a novel sustained release methodology in our Passive Delivery Applicator.
